RC
Avita Medical Inc.
RCEL · NASDAQ
$9.88 -1.69% (-$0.17)
1M +25.06%
Market Cap $245.4M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$7.5
24.1% downside
Current Price
$9.88
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RCEL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
54 /100
Fair P/S 3.25x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 27.66%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 81.56%
Net margin 56.96%
Op. margin 46.57%
Quality
21 /100
Poor ROIC 136.99%
ROA 90.17%
Asset turnover 1.58x
Debt
0 /100
High Current ratio 0.41x
Int. coverage -6.97x
Debt/Equity N/A
Stability
32 /100
Unstable Beta 2.02x
Rev. volatility 17.11%
EPS volatility 49.24%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RCEL
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Cary G. Vance
Employees
226
Headquarters
Valencia
Upcoming events
05 NOV
Earnings
Upcoming earnings report